BioRestorative Therapies, Inc. (BRTX)

Name: BioRestorative Therapies, Inc. (BRTX) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001505497 · Nasdaq · Services-Misc Health & Allied Services, NEC

Sector Services
Incorporated NV
Fiscal year ends Dec 31

For the year ended 2025-12-31, BioRestorative Therapies, Inc. reported revenue of $359.7K. Revenue fell 10.3% from the prior annual period. Over the twelve months to 2026-03-31, revenue was $357.9K.

Key ratios (year ended 2025-12-31)

93.4%

Gross margin

n/m

Operating margin

n/m

Net margin

n/m

Return on year-end equity

-10.3%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-09

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-03-31 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31
Revenue	$357.9K	$359.7K	$401.0K	$145.8K	n/a	n/a	n/a	$119.8K	n/a	n/a	n/a
Cost of Revenue	$28.3K	$23.8K	$28.1K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Gross Profit	$329.6K	$335.9K	$372.9K	$145.8K	n/a	n/a	n/a	n/a	n/a	n/a	n/a
R&D Expense	n/a	$10.09M	$6.71M	$4.03M	n/a	n/a	n/a	$3.51M	n/a	n/a	n/a
Operating Income	-$14.23M	-$15.65M	-$11.56M	-$15.22M	n/a	n/a	n/a	-$18.97M	n/a	n/a	n/a
Depreciation & Amortization	$210.6K	$210.0K	$189.1K	$165.7K	n/a	n/a	n/a	$120.5K	n/a	n/a	n/a
EBITDA	-$14.01M	-$15.44M	-$11.37M	-$15.06M	n/a	n/a	n/a	-$18.85M	n/a	n/a	n/a
Net Income	-$11.06M	-$14.24M	-$8.98M	-$10.42M	n/a	n/a	n/a	-$13.22M	n/a	n/a	n/a
EPS (Diluted)	n/a	-$1.58	-$1.16	-$2.47	n/a	n/a	n/a	-$3.65	n/a	n/a	n/a
Total Assets	$4.64M	$4.08M	$12.28M	$12.61M	n/a	n/a	n/a	$16.43M	n/a	n/a	n/a
Total Liabilities	n/a	n/a	$3.75M	$2.61M	$3.04M	$10.66M	$7.62M	$6.14M	$8.14M	$7.29M	$14.97M
Shareholders' Equity	$3.03M	$356.7K	$8.53M	$10.00M	$10.76M	$2.64M	$6.46M	$10.29M	$9.78M	$12.16M	$5.95M
Cash & Equivalents	$3.11M	$1.51M	$547.9K	$884.4K	n/a	n/a	n/a	$1.71M	n/a	n/a	n/a
Operating Cash Flow	-$11.82M	-$10.79M	-$8.23M	-$6.43M	n/a	n/a	n/a	-$5.91M	n/a	n/a	n/a
Capital Expenditures	n/a	$116.1K	$106.2K	$171.0K	n/a	n/a	n/a	$265.2K	n/a	n/a	n/a
Free Cash Flow	n/a	-$10.91M	-$8.34M	-$6.60M	n/a	n/a	n/a	-$6.18M	n/a	n/a	n/a
Share Repurchases	n/a	$0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Shares Outstanding	25.48M	8.88M	6.92M	4.71M	n/a	n/a	n/a	3.68M	n/a	n/a	n/a
Weighted Average Diluted Shares	n/a	8.99M	7.76M	4.22M	n/a	n/a	n/a	3.62M	n/a	n/a	n/a
EPS (Basic)	n/a	-$1.58	-$1.16	-$2.47	n/a	n/a	n/a	-$3.65	n/a	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView